• Journal of Ocean Engineering and Technology
• /
• v.36 no.4
• /
• pp.211-216
• /
• 2022

Since liquefied natural gas (LNG) is imported in a liquid state of about -162℃ to increase transportation efficiency in Korea, it must be vaporized in a gaseous state to supply it to consumers. Among them, ambient air vaporizer (AAV) has caught attention due to eco-friendly and low costs characteristics. However, there is a disadvantage that the performance of the heat exchanger is deteriorated due to frost due to mist and icing when used for a long time. In this paper, frost generation model in AAV vaporizer was investigated with numerically to examine utilizing the vaporizer performance with the frost generation behavior. The frost generation behavior of AAV vaporizers was examined with humidity, fin characteristic, and temperature effects. As for the LNG discharge temperature, the 12 fin vaporizer showed the highest discharge temperature when the atmospheric temperature was 25℃, and the 8 fin vaporizer had the lowest LNG discharge temperature when the atmospheric temperature was 0℃. In the case of frost formation, in the case of the 12 fin vaporizer, it was formed the most at the atmospheric temperature of 25℃, and the least was formed in the vaporizer at the 0℃ condition of the atmospheric temperature of 8 fins.

• BMB Reports
• /
• v.42 no.1
• /
• pp.59-64
• /
• 2009

Hepatitis B virus (HBV) infection is highly prevalent worldwide. The major challenge for current antiviral treatment is the elevated drug resistance that occurs via rapid viral mutagenesis. In this study, we developed AAV vectors to simultaneously deliver two or three shRNAs targeting different HBV-related genes. These vectors showed markedly better antiviral effects than ones that delivered a single shRNA in vitro. A dual shRNA expression vector (AAV-157i/1694i), which simultaneously expressed two shRNAs targeted the S and X genes of HBV, reduced HBsAg, HBeAg and HBV DNA levels by $87{\pm}4$, $80.3{\pm}2.6$ and $86.2{\pm}7%$ respectively, eight days post-transduction. In a mouse model of prophylactic treatment, HBsAg and HBeAg were reduced to undetectable levels and the serum HBV DNA level was reduced by at least 100 fold. These results indicate that AAV-157i/1694i generates potent anti-HBV effects and that the strategy of constructing multi-shRNA expression vectors may lead to enhanced anti-HBV efficacy and overcome the evading mechanism of the virus and thus the development of drug resistance.

• Asian Pacific Journal of Cancer Prevention
• /
• v.13 no.8
• /
• pp.4031-4036
• /
• 2012

Background: The negative signaling provided by interactions of the co-inhibitory molecule, programmed death-1 (PD-1), and its ligands, B7-H1 (PD-L1) and B7-DC (PD-L2), is a critical mechanism contributing to tumor evasion; blockade of this pathway has been proven to enhance cytotoxic activity and mediate antitumor therapy. Here we evaluated the anti-tumor efficacy of AAV-mediated delivery of the extracellular domain of murine PD-1 (sPD-1) to a tumor site. Material and Methods: An rAAV vector was constructed in which the expression of sPD-1, a known negative regulator of TCR signals, is driven by human cytomegalovirus immediate early promoter (CMV-P), using a triple plasmid transfection system. Tumor-bearing mice were then treated with the AAV/sPD1 construct and expression of sPD-1 in tumor tissues was determined by semi quantitative RT-PCR, and tumor weights and cytotoxic activity of splenocytes were measured. Results: Analysis of tumor homogenates revealed sPD-1 mRNA to be significantly overexpressed in rAAV/sPD-1 treated mice as compared with control levels. Its use for local gene therapy at the inoculation site of H22 hepatoma cells could inhibit tumor growth, also enhancing lysis of tumor cells by lymphocytes stimulated specifically with an antigen. In addition, PD-1 was also found expressed on the surfaces of activated CD8+ T cells. Conclusion: This study confirmed that expression of the soluble extracellular domain of PD-1 molecule could reduce tumor microenvironment inhibitory effects on T cells and enhance cytotoxicity. This suggests that it might be a potential target for development of therapies to augment T-cell responses in patients with malignancies.

• Journal of The Korean Society of Inherited Metabolic disease
• /
• v.5 no.1
• /
• pp.9-17
• /
• 2005

Homocystinuria is a metabolic disorder caused by a deficiency of cystathionine ${\beta}$-synthase (CBS). Patients with homocystinuria show clinical symptoms such as mental retardation, lens dislocation, vascular disease with life-threatening thromboembolisms and skeletal deformities. Generally, the major treatments for CBS deficiency include pharmacologic doses of pyridoxine or dietary restriction of methionine. However, there is no effective treatment for this disease up till today and gene therapy can be an attractive novel approach to treatment of the disease. We investigated whether a recombinant adeno-associated virus could be used as a CBS gene transfer vector to reduce the excessive homocysteine level in the homocystinuria mouse model. Recombinant adeno-associated virus vector encoding the human CBS gene (rAAV-hCBS), driven by EF1-a promoter, was infused into CBS-deficient mice ($CBS^{-/-}$) via intramuscular (IM) and intraperitoneal (IP) injection. IP injection was more efficient than IM injection for prolongation of lives and reduction of plasma homocysteine levels. After 2 weeks of gene transfer by IP injection, serum homocysteine level was significantly decreased in treated mice compared with the age-matched controls and the life span was extended about 1.5 times. Also, increased expression of CBS gene was observed by immunohistochemical staining in livers of treated $CBS^{-/-}$ mice and microvesicular lipid droplets was decreased in cytoplasm of liver. These results demonstrate the possibility and efficacy of gene therapy by AAV gene transfer in homocystinuria mice.

• Journal of Embryo Transfer
• /
• v.25 no.1
• /
• pp.35-42
• /
• 2010

Many studies propose that dysfunction of mitochondrial proton-translocating NADH-ubiquinone oxidoreductase (complex I) is associated with neurodegenerative disorders, such as Parkinson's disease and Huntington's disease. Mammalian mitochondrial proton-translocating NADH-quinone oxidoreductase (complex I) consists of at least 46 different subunits. In contrast, the NDI1 gene of Saccharomyces cerevisiae is a single subunit rotenone-insensitive NADH-quinone oxidoreductase that is located on the matrix side of the inner mitochondrial membrane. With a recombinant adeno-associated virus vector carrying the NDI1 gene (rAAV-NDI1) as the gene delivery method, we were able to attain high transduction efficiencies even in the human epithelial cervical cancer cells that are difficult to transfect by lipofection or calcium phosphate precipitation methods. Using a rAAV-NDI1, we demonstrated that the Ndi1 enzyme is successfully expressed in HeLa cells. The expressed Ndi1 enzyme was recognized to be localized in mitochondria by confocal immunofluorescence microscopic analyses and immunoblotting. Using digitonin-permeabilized cells, it was shown that the NADH oxidase activity of the NDI1-transduced HeLa cells were not affected by rotenone which is inhibitor of complex I, but was inhibited by flavone and antimycin A. The NDI1-transduced cells were able to grow in media containing rotenone. In contrast, control cells that did not receive the NDI1 gene failed to survive. In particular, in the NDI1-transduced cells, the yeast enzyme becomes integrated into the human respiratory chain. It is concluded that the NDI1 gene provides a potentially useful tool for gene therapy of mitochondrial diseases caused by complex I deficiency.

• Journal of the Institute of Electronics Engineers of Korea SC
• /
• v.48 no.6
• /
• pp.43-50
• /
• 2011

Currently, conventional security methods including IC card or password type method are quickly switched into biometric security systems in various applications and the electrocardiogram (ECG) has been considered as one of novel biometrics way. However, conventional ECG based biometrics used lead II signal which conventionally used for formulaic signal to heart disease diagnosis and it is not suitable for biometrics since it is rather difficult to find consistent features for heart disease patents. To overcome this problem, we developed new biometrics system using ECG lead III signals. For wave extraction, signal peak points are extracted through AAV algorithm. For feature selection, extracted waves are categorized into one of four wave types and total twenty two features including number of vertices, wave shapes, amplitude information and interval information are extracted based on their wave types. Experimental results for thirty-six people showed 100% specificity, 95.59% sensitivity and 99.17% of overall identification accuracy.

• Korean Business Review
• /
• v.13
• /
• pp.263-273
• /
• 2000

Mercedes-Benz United States International (MBUSI) built a manufacturing facility for the production of the new M-Class All Activity Vehicle (AAV). This plant consists of three large sequential shops: the Body Shop, the Paint Shop, and the Assembly Shop. When the plant reaches full production, 270 vehicles will be produced each day by two shifts. A finished vehicle is intended to leave the end of the assembly line every 3.6 minutes. The main objective of this study is to simulate the design and operational policies of the AAV assembly facility and to verify that the daily throughput requirements can be met. The simulation study also answered the following questions: What is the maximum throughput (capacity) of the facility? What is the daily distribution of throughput? Does the current design produce the required throughput of 270 cars per day? How do the buffers behave in terms of quantity fluctuations? What are the possible bottlenecks to the desired throughput? This paper provides a description of the integrated simulation model to analyze the capability of the production facilities at MBUSI. This paper includes the inputs used for the development of each of the three individual models: the Body Shop, the Paint Shop, and the Assembly Shop. Additionally, it includes descriptions of the model features and the assumptions that were made.

• Proceedings of the IEEK Conference
• /
• 2006.06a
• /
• pp.791-792
• /
• 2006

본 논문은 심전도의 리드III 파형을 이용하여 신원확인이 가능한 생체인식 기술을 제안한다. 인식을 위한 심전도의 리드III파형을 특징추출하기 위해 $4{\sim}30Hz$의 대역통과 필터를 사용하여 피크(peak)점만 남겨놓고 모든 잡음을 제거한 후, AAV(absolute amplitude value)를 이용하여 피크점의 값을 추출한다. 추출된 피크 점은 원신호의 피크점과 같으므로 이를 기준으로 전체파형을 특징추출을 위한 단위 파형으로 분리한다. 분리된 신호는 정의된 4가지 형태(type)의 파형 중 가장 유사한 파형타입으로 분류되며, 분류된 형태를 기준으로 꼭지점, 최대 피크점, 최소 피크점, 최대.최소 피크점 비, 파형 간격(interval) 및 파형의 세부 모양 등 총22가지의 특징들을 추출한다. 추출된 특징들은 오류역전파 신경회로망(back-propagation neural network)의 입력으로 사용되었으며, 성인남녀 31명을 대상으로 제한된 파형 내에서 실험한 결과 100%의 인식률을 보였다.

• Journal of Life Science
• /
• v.18 no.10
• /
• pp.1395-1399
• /
• 2008

We have recently reported the PRC1 promoter as a promoter candidate to control expression of transcriptionally targeted genes for breast cancer gene therapy. We tested whether the PRC1 promoter could be also applied for the lung cancer gene therapy. In the transient transfection assay with naked plasmids containing the luciferase fused to the PRC1 promoter, the promoter showed little activity in the normal lung cell line, MRC5. However, in the lung cancer A549 cells, PRC1 showed approximately 30-fold activation which was similar to the survivin promoter, the gene whose promoter has been already reportedas a candidate for the gene therapy of lung cancer. In viral systems, the PRC1 promoter showed approximately 75% and 66% of transcriptional activity compared to the CMV promoter in the adeno-associated virus (AAV) and the adenovirus (AV) systems, respectively. However, the PRC1 promoter in either AAV or AV showed approximately 20% activity compared to the CMV promoter in the normal lung cells. In addition, human lung tumor xenograft mice showed that the PRC1 promoter activity was as strong as the CMV activity in vivo. Taken together, these results suggested that PRC1 might be a potential promoter candidate for transcriptionally targeted lung cancer gene therapy.

• Membrane and Water Treatment
• /
• v.2 no.3
• /
• pp.187-205
• /
• 2011

The electric transport of the mixture of hydrochloric and phosphoric acids through strong base (Neosepta ACM) and weak base (Selemion AAV) anion-exchange membranes was investigated. The instantaneous efficiency of HCl removal from the cathode solution, $CE_{Cl}$, with and without $H_3PO_4$ was determined. It was found that $CE_{Cl}$ was 0.8-0.9 if the number of moles of elementary charge passed through the system, $n_F$, did not exceed ca. 80% of the initial number of HCl moles in the cathode solution, $n_{Cl,ca,0}$. The retention efficiency of $H_3PO_4$ in that range was close to one. The transport of acid mixtures was satisfactorily described by a model based on the extended Nernst-Planck and Donnan equations for $n_F$ not exceeding $n_{Cl,ca,0}$. Among the tested model parameters, most important were: concentration of fixed charges, the porosity-tortuosity coefficient, and the partition coefficient of an undissociated form of $H_3PO_4$. For the both membranes, the obtained optimal values of fixed charge concentration, $\bar{c}_m$, were up to 40% lower than the literature values of $\bar{c}_m$ obtained from the equilibrium measurements. Regarding the $H_3PO_4$ equilibria, it was sufficient to consider $H_3PO_4$ as a monoprotic acid.